Advertisement covers IDWeek 2012

Medical News

Simplifying HAART Regimen Fails to Maintain HIV-1 Viral Suppression

October 23, 2012

A pilot study by Harold P. Katner, M.D., of Mercer University School of Medicine in Macon, Ga., and colleagues assessed the durability of HIV-1 virologic suppression in persons who changed from a lopinavir/ritonavir-based triple highly active antiretroviral therapy (HAART) regimen once or twice a day to lopinavir/ritonavir monotherapy once daily. This was an observational cohort study to determine the proportion of subjects who sustained virologic suppression through the 48th week following their switch to the daily lopinavir/ritonavir monotherapy. Researchers presented the study at IDWeek 2012, a joint meeting of the Infectious Diseases Society of America (IDSA), the Society for Health and Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS).

A total of 13 individuals began lopinavir/ritonavir-based HAART therapy and maintained HIV-1 viral loads <75 copies/mL) for 48 weeks before enrollment in the study; three failed screening -- two due to elevated viral loads and one because of an inability to tolerate lopinavir/ritonavir daily. The research continued with 10 individuals, two female and six male African Americans and one male and one female Caucasian. Subjects were 27-53 years old, and the mean duration of their therapy before de-escalation was 252 weeks (105-413 weeks). Mean CD4 count at baseline was 338 cells/mm3 (range 120-512 cells/mm3). Subjects received frequent clinical, virologic, and immunologic monitoring.

One subject completed 48 weeks of daily lopinavir/ritonavir monotherapy and one withdrew at 22 weeks after experiencing two detectable viral loads five weeks apart. Four subjects had virologic failure, one of whom developed multiple nucleoside and protease inhibitor mutations. The study was terminated. None of the subjects reported severe adverse events.

Back to other news for October 2012

Adapted from:
Monthly Prescribing Reference
10.21.2012; Debra Hughes

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.